Zhejiang Hisun Pharmaceutical News

Zhejiang Hisun Pharmaceutical Registers Cancer Drug in China

MT NewswiresJan 10 14:53

Express News | Zhejiang Hisun Pharmaceutical: Everolimus tablets have obtained pharmaceutical registration certificates.

BreakingsJan 9 17:08

Zhejiang Hisun Pharmaceutical (600267.SH): plans to invest 50 million yuan in Jisheng Aoma's capital increase.

On December 27, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that Nanjing Jisheng Aoma Biomedical Co., Ltd. (referred to as "Jisheng Aoma") was established in 2021, and its main product indications include allergic rhinitis, allergic dermatitis, respiratory infections, vaccine adjuvants, etc. To support its own Innovative Drugs development, Jisheng Aoma recently plans to raise no more than 0.1 billion yuan. Given that the disease areas of Jisheng Aoma's pipeline products align with the company's Global Strategy, to promote cooperation with Jisheng Aoma and advance the company’s own Innovative Drugs development, it is agreed that the company will participate in this round of capital increase with its self-raised funds amounting to 50 million yuan, if...

Gelonghui FinanceDec 27, 2024 17:13

Zhejiang Hisun Pharmaceutical (600267): Improvement in operational margins and upgrade of the synthetic biology platform.

The operation situation has marginally improved, with the net income attributable to the parent company reaching a record high after excluding non-recurring items. As the impact of not winning bids in the multi-national centralized procurement gradually becomes apparent, the company's operating situation has significantly improved. In the first three quarters of 2024, the company achieved a net income of 5.15.

Western SecuritiesDec 27, 2024 16:07

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24

Zhejiang Hisun Pharmaceutical (600267.SH): Apremilast tablets and posaconazole enteric-coated tablets are expected to win centralized procurement bidding.

Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in a joint procurement...

Zhitong FinanceDec 13, 2024 19:08

Zhejiang Hisun Pharmaceutical (600267.SH): Participation in the national pharmaceutical centralized procurement aims to win the bid.

Gelonghui reported on December 13 that Zhejiang Hisun Pharmaceutical (600267.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). After the opening and evaluation of bids by the Joint Procurement Office, the company's products, Aprepitant tablets and Posaconazole enteric-coated tablets, are proposed to win the bid for this centralized procurement. Aprepitant tablets and Posaconazole enteric-coated tablets have been selected for supply provinces based on the market potential of each province, and the results of the selection will be officially announced after being posted by the Joint Procurement Office.

Gelonghui FinanceDec 13, 2024 18:42

Express News | Zhejiang Hisun Pharmaceutical: The company's products Apremilast tablets and Posaconazole enteric-coated tablets are proposed to be awarded national centralized pharmaceutical procurement.

BreakingsDec 13, 2024 18:35

Express News | Zhejiang Hisun Pharmaceutical: Subsidiary receives approval numbers for two veterinary drug products.

BreakingsNov 28, 2024 17:05

Zhejiang Hisun Pharmaceutical (600267.SH): Meropenem is currently in the first round of centralized procurement period, with not a large sales volume

Gelonghui reported on November 15 that zhejiang hisun pharmaceutical (600267.SH) stated on the interactive platform that meropenem is still in the first round of centralized procurement, and the sales are not large. The company will closely monitor subsequent procurement opportunities; by diversifying its operations, the company has shown good recovery. The entire company is working hard to achieve the performance goals set at the beginning of the year. The company's industrial team continues to improve process levels, and the cost reduction and efficiency enhancement efforts have seen results this year. Substantial progress in industrial capacity recovery is expected to occur starting next year.

Gelonghui FinanceNov 15, 2024 16:16

China Approves Hisun Pharma's Two Medications for Dogs

MT NewswiresNov 15, 2024 16:00

Haizheng Pharmaceutical: Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 31, 2024 00:00 · Announcements

Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 31, 2024 00:00 · Announcements

Express News | Zhejiang Hisun Pharmaceutical: Net income in the third quarter increased by 109.37% year-on-year.

BreakingsOct 30, 2024 23:47

Zhejiang Hisun Pharmaceutical (600267.SH): The net income for the first three quarters was 0.515 billion yuan, a year-on-year increase of 16.49%.

GeLongHui October 30th| Zhejiang Hisun Pharmaceutical (600267.SH) released its third-quarter report, with revenue for the first three quarters at 7.87 billion yuan, a 9.50% decrease year-on-year. Net income was 0.515 billion yuan, a 16.49% year-on-year increase. Non-GAAP net income was 0.346 billion yuan, an 8.80% year-on-year increase, with basic earnings per share of 0.44 yuan.

Gelonghui FinanceOct 30, 2024 21:28

Express News | Zhejiang Hisun Pharmaceutical has completed the change of leadership in business registration, with Xiao Weihong appointed as the chairman.

BreakingsOct 24, 2024 11:38

Hisun Pharma Unit Gets Regulatory Nod for Cat Vaccine

MT NewswiresOct 23, 2024 14:40

Zhejiang Hisun Pharmaceutical (600267.SH) passed the pharmaceutical GMP compliance inspection.

zhejiang hisun pharmaceutical (600267.SH) announced that the company obtained the pharmaceutical GMP certification from the Zhejiang Provincial Food and Drug Administration website...

Zhitong FinanceOct 14, 2024 17:31

Hisun Pharmaceutical's Parent Nominates Candidate for Chairman

MT NewswiresOct 2, 2024 16:02

Hisun Pharmaceutical to Pay Additional Taxes Worth 18 Million Yuan

MT NewswiresOct 2, 2024 15:54